Oliver Perez

Summary

Affiliation: Finlay Institute
Country: Cuba

Publications

  1. ncbi New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization
    Maribel Cuello
    Immunology Department, Finlay Institute, Cuba
    Vaccine 25:1798-805. 2007
  2. pmc Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
    O Perez
    Immunology Department, Research Vice Presidency, Finlay Institute, Havana City, Cuba
    Braz J Med Biol Res 45:681-92. 2012
  3. doi 4th International Workshop in Vaccine Adjuvants and Parasitic Vaccines (adjuvant 2008)
    Oliver Perez
    Department of Immunology, Research Vice Presidency, Finlay Institute, PO Box 16017, Havana, Cuba
    Expert Rev Vaccines 7:1151-3. 2008
  4. ncbi New vaccines require potent adjuvants like AFPL1 and AFCo1
    O Perez
    Immunology Department, Finlay Institute, Havana City, Cuba
    Scand J Immunol 66:271-7. 2007
  5. ncbi Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-52-3. 2006
  6. ncbi 2nd International Workshop on Vaccine Adjuvants and Glycoconjugates, Varadero, Cuba, 11-15 April 2004
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-1-2. 2006
  7. pmc Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine
    O Perez
    Department of Basic and Clinical Immunology, Finlay Institute, Havana City, Cuba
    Infect Immun 69:4502-8. 2001
  8. ncbi Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern
    Oliver Perez
    Immunology Department, Finlay Institute, Havana, Cuba
    Immunol Cell Biol 82:603-10. 2004
  9. pmc Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B
    Caridad Zayas
    Finlay Institute, Ave 27 No 19805, La Lisa, Havana, Cuba, AP 16017, CP11600
    BMC Immunol 14:S4. 2013
  10. ncbi Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants
    Judith Del Campo
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-50-1. 2006

Collaborators

Detail Information

Publications35

  1. ncbi New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization
    Maribel Cuello
    Immunology Department, Finlay Institute, Cuba
    Vaccine 25:1798-805. 2007
    ..A change in the immunological pattern of responses of PsC, from TI-2 to a thymus-dependent (TD) pattern, was also demonstrated...
  2. pmc Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
    O Perez
    Immunology Department, Research Vice Presidency, Finlay Institute, Havana City, Cuba
    Braz J Med Biol Res 45:681-92. 2012
    ..A summary of toxicology and regulatory issues will also be discussed, and the Finlay Adjuvant Platform is briefly summarized...
  3. doi 4th International Workshop in Vaccine Adjuvants and Parasitic Vaccines (adjuvant 2008)
    Oliver Perez
    Department of Immunology, Research Vice Presidency, Finlay Institute, PO Box 16017, Havana, Cuba
    Expert Rev Vaccines 7:1151-3. 2008
    ..Five keynote addresses, 21 oral presentations and 28 posters were presented, and the meeting was ended with a 'hot-topic' session discussing future challenges. This article highlights the most important issues discussed...
  4. ncbi New vaccines require potent adjuvants like AFPL1 and AFCo1
    O Perez
    Immunology Department, Finlay Institute, Havana City, Cuba
    Scand J Immunol 66:271-7. 2007
    ..Both are very promising adjuvants...
  5. ncbi Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-52-3. 2006
    ..Thus, our results suggest that PL-derived Cochleate can be used as a promising immunomodulator and delivery system for the development of mucosal, particularly nasal vaccines...
  6. ncbi 2nd International Workshop on Vaccine Adjuvants and Glycoconjugates, Varadero, Cuba, 11-15 April 2004
    Oliver Perez
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-1-2. 2006
  7. pmc Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine
    O Perez
    Department of Basic and Clinical Immunology, Finlay Institute, Havana City, Cuba
    Infect Immun 69:4502-8. 2001
    ..In conclusion, we have shown that, at least in the Cuban adult population, VA-MENGOC-BC induces mechanisms with a T-helper 1 pattern in the afferent and effector branches of the immune response...
  8. ncbi Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern
    Oliver Perez
    Immunology Department, Finlay Institute, Havana, Cuba
    Immunol Cell Biol 82:603-10. 2004
    ..In conclusion, our results support the use of PLCS as a potent Th1 adjuvant for parenteral and mucosal vaccines...
  9. pmc Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B
    Caridad Zayas
    Finlay Institute, Ave 27 No 19805, La Lisa, Havana, Cuba, AP 16017, CP11600
    BMC Immunol 14:S4. 2013
    ..The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated...
  10. ncbi Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants
    Judith Del Campo
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-50-1. 2006
    ..These results show that Cochleate and PL are capable of inducing both systemic and mucosal antibody responses as well as a Th1 type of immunity as evidenced by high gammaIFN and IgG2a antibody responses...
  11. ncbi Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery
    Tamara Rodríguez
    Department of Immunology, Finlay Institute, PO Box 16017, Havana, Cuba
    Vaccine 23:1312-21. 2005
    ..The work also shows the potential of PL as a general system to deliver antigens to DC for presentation to CD4+ and CD8+ T-cells...
  12. doi AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses
    Belkis Romeu
    Immunology Department, Havana, Cuba
    Scand J Infect Dis 43:809-13. 2011
    ..In summary, AFCo1 as nasal adjuvant was demonstrated to be capable of eliciting mucosal and systemic specific responses against a TI antigen...
  13. ncbi Proteoliposome derived cochleate as novel adjuvant
    Gustavo Bracho
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-30-1. 2006
    ..The results and the easy capability for new antigen incorporation on CS support its use as adjuvant for immunization with a large variety of pathogen derived antigens and different routes of immunization...
  14. pmc Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi
    Reinaldo Acevedo
    Research and Development Vice presidency of Finlay Institute, Havana, Cuba
    BMC Immunol 14:S10. 2013
    ..In conclusion, this work demonstrates that PLc can be used as a mucosal adjuvant to potentiate the immune response against a polysaccharide antigen like Poli Vi...
  15. pmc AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5
    Gustavo Bracho
    Department of Immunology, Finlay Institute, Havana City, Cuba
    Malar J 8:35. 2009
    ....
  16. ncbi Scale up of proteoliposome derived Cochleate production
    Caridad Zayas
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-94-5. 2006
    ..This work demonstrates that CFS is very efficient process to obtain Cochleate structures with a yield of more than 80% and the immunogenicity comparable to that obtained by dialysis membrane...
  17. ncbi Strategy for determination of an efficient Cochleate particle size
    Danay Gil
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-92-3. 2006
    ..The best treatment parameter for mechanical stress of the Cochleate was prolonged treatment with untrasonic low frequency waves...
  18. doi Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice
    Reinaldo Acevedo
    Immunology Department, Bacterial Vaccines Division of Finlay Institute, Havana, Cuba
    Methods 49:309-15. 2009
    ..These results show for the first time that AFCo2 can be obtained from V. cholerae O1 proteoliposomes and have the potential to protect against the pathogen when administered intranasally...
  19. ncbi Mucosal immune responses to meningococcal C polysaccharide-protein conjugate in mice
    Maribel Cuello
    Immunology Department, Finlay Institute, 27 Avenue No 19805, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-72-3. 2006
    ..These results indicated that after conjugation, there was a change in the responses for MGCP from thymus-independent to thymus-dependent and that it was effective by intranasal route...
  20. doi The golden era of vaccine adjuvants
    Osmir Cabrera
    Department of Immunology, Finlay Institute, PO Box 16017, Havana, Cuba
    Expert Rev Vaccines 10:1007-9. 2011
    ..This article highlights the most important issues presented...
  21. doi Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1
    Belkis Romeu
    Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba
    Can J Microbiol 57:256-61. 2011
    ..These data support the fact that AFCo1 is a potent mucosal adjuvant in nasal immunization to a coadministered protein antigen...
  22. ncbi Adjuvant properties of lipopolysaccharide from Neisseria meningitidis serogroup B detoxified and conjugated with tetanus toxoid
    Julio A Balboa
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-63-4. 2006
    ..These results evidence the adjuvant activity of detoxified LPS and may suggest that the conjugation to TT changes the LPS immune response from thymus-independent to thymus-dependent...
  23. ncbi Bacterial derived proteoliposome for allergy vaccines
    Miriam Lastre
    Immunology Department, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-34-5. 2006
    ..The low dose was more effective than high dose. These results clearly support the potential use of PL as possible adjuvants for anti-allergic vaccines...
  24. ncbi Validation of colorimetric assay to detect complement-mediated antibody-dependent bactericidal activity against serogroups B and C Neisseria meningitidis
    Tamara Rodríguez
    Department of Immunology, Direction of Bacterial Vaccines and Direction of Control of Quality, Finlay Institute, 27 Ave, b 198 and 202, PO Box 16017, La Lisa, Havana, Cuba
    Biologicals 31:209-12. 2003
    ..Concluding, cSBA showed to be highly precise, allowing also the use of freeze-dried complement which is another important advantage for this kind of assay...
  25. doi Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice
    Judith Del Campo
    Department of Immunology, Finlay Institute, Havana, Cuba
    Vaccine 28:1193-200. 2010
    ..These data may have implications for the development of a mucosal vaccine against genital herpes...
  26. ncbi The adjuvant potential of synthetic alkylglycerols
    Reinaldo Acevedo
    Department of Immunology, Finlay Institute, P O Box 16017, Havana, Cuba
    Vaccine 24:S2-32-3. 2006
    ..These results indicate that synthetic AGs are effective adjuvants for the standardized antigen, Ova...
  27. pmc Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay
    Tamara Rodríguez
    Department of Basic and Clinical Immunology, Finlay Institute, 27 avenue 198 and 202, La Lisa, P O Box 16017, Havana City, Cuba
    Clin Diagn Lab Immunol 9:109-14. 2002
    ..974, P < 0.01). The standardized cSBA allows easy, fast, and efficient evaluation of samples...
  28. doi Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A
    Belkis Romeu
    Immunology Department, Vice presidency of Research and Development, Havana, Cuba
    Immunol Res 58:75-85. 2014
    ..Memory B cells and long-term memory T cells were also detected. The results of this study indicate that combined meningococcal serogroup A and W135 OMV can activate cell-mediated immunity and induce a long-term memory response. ..
  29. pmc Cochleates derived from Vibrio cholerae O1 proteoliposomes: the impact of structure transformation on mucosal immunisation
    Reinaldo Acevedo
    Research and Development Vice presidency of Finlay Institute, Havana, Cuba
    PLoS ONE 7:e46461. 2012
    ....
  30. doi A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice
    Jose Luis Perez
    Instituto Finlay, Centro de Investigación y Producción de Vacunas, Ave 27, No 19805, La Lisa, A P 16017 Cod 11600, Ciudad de La Habana, Cuba
    Vaccine 27:205-12. 2009
    ..70+/-0.23) after two weeks from last dose. These results show for the first time that PL can be obtained from V. cholerae O1 and when administer by intranasal route has the potential to protect against this pathogen...
  31. doi Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?
    Belkis Romeu
    Immunology Department, Research and Development, Finlay Institute, Havana, Cuba
    J Drug Target 20:502-8. 2012
    ....
  32. doi 2nd international workshop on Neisseria vaccines (Neisseria vaccines 2009)
    Belkis Romeu
    Finlay Institute, PO Box 16017, Havana, Cuba
    Expert Rev Vaccines 8:987-92. 2009
    ..The meeting was concluded with a 'Hot Topics' session discussing future challenges. This article highlights the most important issues presented...
  33. doi Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model
    D Fuentes
    National Center for Laboratory Animal Breeding, Havana, Cuba
    Breast Cancer Res Treat 120:379-89. 2010
    ..This data may provide a rational for chemo-immunotherapy combinations with potential medical implications in breast cancer...
  34. ncbi Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
    G Gonzalez
    Center of Molecular Immunology, Hermanos Ameijeiras Hospital, Havana, Cuba
    Ann Oncol 14:461-6. 2003
    ..Two pilot clinical trials were conducted to examine the safety and immunogenicity of a five-dose immunization protocol and to compare different adjuvants and treatment designs...